NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
Clinical Trials
39 trialsNCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT04900818 2026-03-05
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
Phase 1 Recruiting
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT05076760 2025-08-29
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
Phase 1 Recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02628574 2025-08-03
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
Phase 1 Completed
NCT05180799 2025-06-15
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla, Inc.
Phase 1/2 Active not recruiting
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT02259231 2025-06-04
RTA 408 Capsules in Patients With Melanoma - REVEAL
Biogen
Phase 1/2 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT03523572 2025-01-27
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Phase 1 Completed
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT02860546 2024-09-03
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Taiho Oncology, Inc.
Phase 2 Completed
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT02848443 2024-07-25
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
Phase 1 Completed
NCT04200963 2024-03-15
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
Phase 1 Completed
NCT04892043 2024-02-23
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Terminated
NCT04084951 2023-04-14
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Completed
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT03785925 2023-03-28
PIVOT-10
Nektar Therapeutics
Phase 2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT04069936 2022-08-02
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILsâ„¢ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
WindMIL Therapeutics
Phase 2 Terminated
NCT01354431 2022-05-12
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 2 Completed
NCT05068609 2022-05-05
VOLUME-PRO
Bristol-Myers Squibb
Completed
NCT02636036 2021-11-09
SPICE
Akamis Bio
Phase 1 Completed
NCT03952325 2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT02842125 2020-06-02
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
MultiVir, Inc.
Phase 1/2 Terminated
NCT02944396 2019-10-23
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1 Completed